Lilly's Zepbound scores 2nd approval with landmark FDA nod in obstructive sleep apnea
Christmas has come early for Eli Lilly this year, courtesy of a fresh FDA approval for the Indianapolis drugmaker’s obesity star Zepbound. | Thanks to a new FDA green light, Lilly’s dual GIP/GLP-1 blockbuster Zepbound has become the first prescription medicine cleared to treat adults with moderate-to-severe obstructive sleep apnea and obesity.
Lilly's weight-loss treatment Zepbound becomes first FDA-approved drug for sleep apnea
(Reuters) -The U.S. Food and Drug Administration on Friday approved Eli Lilly's weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug greenlighted to directly treat patients with the common sleeping disorder.
Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for ...
The Food and Drug Administration (FDA) has reaffirmed that Mounjaro and Zepbound are no longer in shortage following a ...
Eli Lilly just gave investors several reasons to cheer.
After a stunning 703% run-up in price over the past five years, shares of Eli Lilly and Co. have been on a roller-coaster ...
The Food and Drug Administration said Thursday that the longstanding shortage of Eli Lilly’s weight-loss drug Zepbound and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback